Trials / Completed
CompletedNCT00220103
Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma
Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Royal Marsden NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable oesophageal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epirubicin, capecitabine, cisplatin | |
| PROCEDURE | Surgical resection |
Timeline
- Start date
- 2002-11-01
- First posted
- 2005-09-22
- Last updated
- 2009-12-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00220103. Inclusion in this directory is not an endorsement.